Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2019’, provides an overview of the Systemic Sclerosis (Scleroderma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma)

- The report reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Systemic Sclerosis (Scleroderma) therapeutics and enlists all their major and minor projects

- The report assesses Systemic Sclerosis (Scleroderma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Systemic Sclerosis (Scleroderma)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abide Therapeutics Inc

Accuitis Pharmaceuticals Inc

AnaMar AB

Anima Biotech Inc

arGentis Pharmaceuticals LLC

AstraZeneca Plc

Biogen Inc

Boehringer Ingelheim GmbH

BriaCell Therapeutics Corp

Bristol-Myers ...

Abide Therapeutics Inc

Accuitis Pharmaceuticals Inc

AnaMar AB

Anima Biotech Inc

arGentis Pharmaceuticals LLC

AstraZeneca Plc

Biogen Inc

Boehringer Ingelheim GmbH

BriaCell Therapeutics Corp

Bristol-Myers Squibb Co

Capella Bioscience Ltd

Chugai Pharmaceutical Co Ltd

Covis Pharmaceuticals Inc

CSL Ltd

Cumberland Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Emerald Health Sciences Inc

Fibrocell Science Inc

Forbius

Fresenius SE & Co KGaA

Galapagos NV

GenKyoTex SA

Gilead Sciences Inc

GlaxoSmithKline Plc

GNI Group Ltd

iBio Inc

Kadmon Corp LLC

Leadiant Biosciences Inc

Link Genomics Inc

Nuevolution AB

Panorama Research Inc

Patagonia Pharmaceuticals LLC

PDX Pharmaceuticals LLC

Peptinov SAS

Pfizer Inc

ProMetic Life Sciences Inc

Resolys Bio Inc

Ribomic Inc

Samumed LLC

Sanofi

Seattle Genetics Inc

Stemline Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Unity Biotechnology Inc

Table of Contents

Table of Contents

Introduction

Systemic Sclerosis (Scleroderma) – Overview

Systemic Sclerosis (Scleroderma) – Therapeutics Development

Systemic Sclerosis (Scleroderma) – Therapeutics Assessment

Systemic Sclerosis (Scleroderma) – Companies Involved in Therapeutics ...

Table of Contents

Introduction

Systemic Sclerosis (Scleroderma) – Overview

Systemic Sclerosis (Scleroderma) – Therapeutics Development

Systemic Sclerosis (Scleroderma) – Therapeutics Assessment

Systemic Sclerosis (Scleroderma) – Companies Involved in Therapeutics Development

Systemic Sclerosis (Scleroderma) – Drug Profiles

Systemic Sclerosis (Scleroderma) – Dormant Projects

Systemic Sclerosis (Scleroderma) – Discontinued Products

Systemic Sclerosis (Scleroderma) – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Tables

Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Abide Therapeutics Inc, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Accuitis Pharmaceuticals Inc, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by AnaMar AB, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Anima Biotech Inc, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by arGentis Pharmaceuticals LLC, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by AstraZeneca Plc, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Biogen Inc, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Boehringer Ingelheim GmbH, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by BriaCell Therapeutics Corp, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Bristol-Myers Squibb Co, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Capella Bioscience Ltd, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Chugai Pharmaceutical Co Ltd, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Covis Pharmaceuticals Inc, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by CSL Ltd, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Cumberland Pharmaceuticals Inc, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Emerald Health Sciences Inc, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Fibrocell Science Inc, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Forbius, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Fresenius SE & Co KGaA, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Galapagos NV, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by GenKyoTex SA, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Gilead Sciences Inc, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by GlaxoSmithKline Plc, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by GNI Group Ltd, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by iBio Inc, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Kadmon Corp LLC, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Leadiant Biosciences Inc, H1 2019

Systemic Sclerosis (Scleroderma) – Pipeline by Link Genomics Inc, H1 2019

List of Figures

List of Figures

Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Figures

Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports